Add thelocalreport.in As A Trusted Source
danish Novo Nordisk Will be available in 1.5 mg and 4 mg Wegowe weight loss pills The company said on Monday it would offer self-pay patients in the United States for $149 a month starting Jan. 5.
The company said on its website that it will offer the highest-dose pills, 9 mg and 25 mg, starting on the same date, priced at $299 per month.
It is said that starting April 15, the price of a 4 mg dose will increase to $199 per month.
this U.S. Food and Drug Administration The FDA approved the drug on Dec. 22, setting the stage for Novo Nordisk to regain ground lost to rival Eli Lilly.
Semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic and will be sold under the Wegovy brand name. Novo Nordisk already markets oral semaglutide Rybelsus for the treatment of type 2 diabetes.
U.S. regulator approves version of the pill wiggs This marks the first time a daily oral medication has been approved to treat obesity.
The change is expected to further drive adoption of the already widely popular technology GLP-1 drugs and helping fight chronic obesity around the world.
“We now have a once-daily pill that has an injection-like effect,” said David Moore, executive vice president of U.S. operations at Novo Nordisk, the maker of Wegovy. Tell wall street journal then. “This is a change from where we were before
Some people avoid weight-loss injections because of their high cost (up to $1,000 per month), as well as insurance issues and fear of needles. It is hoped that the launch of more affordable drugs will open up a wider market for these drugs.
“This is a meaningful step forward for the field,” said gastroenterologist Dr. Christopher McGowan, who runs a weight-loss clinic in Cary, North Carolina. Tell NBC News. “It won’t replace injectables, but it broadens our toolkit in important ways.”
“Pills are familiar, not intimidating, and fit more naturally into most people’s daily lives,” he added.